Get the Stockscreener App
0.8085
1.19%
0.0095
After Hours:
.82
0.0115
+1.42%
Allovir Inc stock is traded at $0.8085, with a volume of 88,639.
It is up +1.19% in the last 24 hours and up +3.75% over the past month.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
See More
Previous Close:
$0.799
Open:
$0.771
24h Volume:
88,639
Relative Volume:
0.32
Market Cap:
$93.40M
Revenue:
-
Net Income/Loss:
$-168.86M
P/E Ratio:
-0.4517
EPS:
-1.79
Net Cash Flow:
$-125.29M
1W Performance:
+3.80%
1M Performance:
+3.75%
6M Performance:
+7.10%
1Y Performance:
-62.40%
1-Day Range:
$0.7657
$0.8096
1-Week Range:
$0.7508
$0.8096
52-Week Range:
$0.58
$2.485
Allovir Inc Stock (ALVR) Company Profile
Name
Allovir Inc
Sector
Industry
Phone
(617) 433-2605
Address
1100 WINTER STREET, WALTHAM
Allovir Inc Stock (ALVR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | JP Morgan | Overweight |
| Aug-24-20 | Initiated | Morgan Stanley | Overweight |
| Aug-24-20 | Initiated | SVB Leerink | Outperform |
Allovir Inc Stock (ALVR) Latest News
AlloVir (NASDAQ:ALVR) Shares Up 1% - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Holdings Lowered by Acadian Asset Management LLC - Defense World
AlloVir (NASDAQ:ALVR) Trading 1% Higher - MarketBeat
Kuehn Law Encourages Investors of AlloVir, Inc. to Contact Law Firm - ForexTV.com
Upward Trajectory: AlloVir Inc (ALVR) Posts a Gaine, Closing at 0.78 - The Dwinnex
Investigation announced for Investors who lost money with - openPR
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Head to Head Analysis: Vaxcyte (NASDAQ:PCVX) & AlloVir (NASDAQ:ALVR) - Defense World
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com India
Allovir CEO Diana Brainard sells shares worth nearly $4,000 By Investing.com - Investing.com Australia
Allovir CEO Diana Brainard sells shares worth nearly $4,000 - Investing.com
Allovir executive sells shares to cover tax obligations - Investing.com
Allovir CEO Diana Brainard sells shares worth over $2,300 - Investing.com
Vanguard Group Inc. Lowers Position in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Price T Rowe Associates Inc. MD Buys 54,900 Shares of AlloVir, Inc. (NASDAQ:ALVR) - Defense World
ALVR (AlloVir) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
AlloVir (NASDAQ:ALVR) Posts Earnings Results, Beats Expectations By $0.05 EPS - Defense World
B of A Securities Initiates Coverage of AlloVir (ALVR) with Buy Recommendation - MSN
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
Analyzing Immunovant (NASDAQ:IMVT) & AlloVir (NASDAQ:ALVR) - Defense World
AlloVir Inc (ALVR) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Yahoo Finance
AlloVir, Inc. (NASDAQ:ALVR) Sees Large Decline in Short Interest - MarketBeat
Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 6.3% - American Banking and Market News
Short Interest in AlloVir, Inc. (NASDAQ:ALVR) Decreases By 6.3% - Defense World
Acadian Asset Management LLC Has $1.20 Million Stake in AlloVir, Inc. (NASDAQ:ALVR) - Defense World
Acadian Asset Management LLC Buys 1,387,666 Shares of AlloVir, Inc. (NASDAQ:ALVR) - MarketBeat
Allovir's general counsel sells over $1,000 in stock - Investing.com
Allovir executive sells over $2500 in company stock - Investing.com
Allovir executive sells over $2500 in company stock By Investing.com - Investing.com Canada
Parainfluenza Virus Infection Drugs Market Size 2032 | - openPR
AlloVir, Inc. Expected to Earn Q2 2024 Earnings of ($0.07) Per Share (NASDAQ:ALVR) - Defense World
AlloVir, Inc. (NASDAQ:ALVR) Forecasted to Post Q2 2024 Earnings of ($0.07) Per Share - MarketBeat
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely - Simply Wall St
Investing in AlloVir Inc (ALVR) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
AlloVir (NASDAQ:ALVR) Trading Up 3.3% - MarketBeat
AlloVir (NASDAQ:ALVR) Trading Up 3.3% - Defense World
Taking a Closer Look At AlloVir Inc (ALVR) Following Its Recent Trade - Knox Daily
AlloVir Investor Deadline Approaching - Newsfile
Allovir CEO Diana Brainard sells shares worth over $1,000 By Investing.com - Investing.com Canada
Jacobs solutions executive chair sells $979k in stock By Investing.com - Investing.com
Allovir CEO Diana Brainard sells shares worth over $1,000 By Investing.com - Investing.com India
Eliem Therapeutics EVP sells $338,000 in stock By Investing.com - Investing.com India
Taking a Closer Look At AlloVir Inc (ALVR) Following Its Recent Trade – Knox Daily - Knox Daily
Nothing is Better Than AlloVir Inc (ALVR) stock at the moment – Sete News - SETE News
SEC Form 144 filed by AlloVir Inc. - Quantisnow
AlloVir ends lease early, pays $7 million termination fee - Investing.com
AlloVir Finalizes $7 Million Lease Termination Deal - TipRanks
AlloVir ends lease early, pays $7 million termination fee By Investing.com - Investing.com UK
Is AlloVir Inc (ALVR) worth investing in despite its overvalued state? – US Post News - US Post News
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% - Yahoo New Zealand News
Allovir Inc Stock (ALVR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):